251112-24-0

Basic information

• Product Name: N'-[(1S)-1-[[[(1S,2R)-3-[(2S)-2-[[(1,1-Dimethylethyl)amino]carbonyl]-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]-N-methyl-N-[2-(1-methylethyl)-4-thiazolylmethyl]urea
• Synonyms: N'-[(1S)-1-[[[(1S,2R)-3-[(2S)-2-[[(1,1-Dimethylethyl)amino]carbonyl]-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]-N-methyl-N-[2-(1-methylethyl)-4-thiazolylmethyl]urea
• CAS NO: 251112-24-0
• Molecular Weight: 643.894
• Mol File: 251112-24-0.mol

Chemical Properties

• CAS DataBase Reference: N'-[(1S)-1-[[[(1S,2R)-3-[(2S)-2-[[(1,1-Dimethylethyl)amino]carbonyl]-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]-N-methyl-N-[2-(1-methylethyl)-4-thiazolylmethyl]urea(CAS DataBase Reference)
• NIST Chemistry Reference: N'-[(1S)-1-[[[(1S,2R)-3-[(2S)-2-[[(1,1-Dimethylethyl)amino]carbonyl]-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]-N-methyl-N-[2-(1-methylethyl)-4-thiazolylmethyl]urea(251112-24-0)
• EPA Substance Registry System: N'-[(1S)-1-[[[(1S,2R)-3-[(2S)-2-[[(1,1-Dimethylethyl)amino]carbonyl]-1-piperazinyl]-2-hydroxy-1-(phenylmethyl)propyl]amino]carbonyl]-2-methylpropyl]-N-methyl-N-[2-(1-methylethyl)-4-thiazolylmethyl]urea(251112-24-0)

Safety Data

• Hazardous Substances Data: 251112-24-0(Hazardous Substances Data)

Upstream product

• 159572-17-5 (S)-4-((2R,3S)-3-Amino-2-hydroxy-4-phenyl-butyl)-3-tert-butylcarbamoyl-piperazine-1-carboxylic acid tert-butyl ester 
• 154212-61-0 N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)-carbonyl)-L-valine 
• 251112-23-9 (S)-3-tert-Butylcarbamoyl-4-((2R,3S)-2-hydroxy-3-{(S)-2-[3-(2-isopropyl-thiazol-4-ylmethyl)-3-methyl-ureido]-3-methyl-butyrylamino}-4-phenyl-butyl)-piperazine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Retroviral protease inhibiting compounds

The present invention discloses novel compounds, compositions, and methods for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease. The present invention also relates to compositions and methods for

Potent piperazine hydroxyethylamine HIV protease inhibitors containing novel P3 ligands

The 2-isopropyl thiazolyl group is a highly optimized P3 ligand for C2 symmetry-based HIV protease inhibitors, as exemplified in the drag ritonavir. Here we report that incorporation of this P3 ligand into a piperazine hydroxyethylamine series also yielded novel, highly potent inhibitors. In tissue culture assays, the presence of human serum was less deleterious to the activity of these inhibitors than to that of ritonavir. Furthermore, potent activity against ritonavir resistant HIV was observed.